KL-A293

N/A

Report date: 2022/07/15 15:58:54

Base Information

Drug NameKL-A293
Drug Alias NameKL-A293
ClassificationBiologics
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAnyuan Pharmaceutical Technology (Shanghai) Co LtdSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan Kelun-Biotech Biopharmaceutical Co LtdAnyuan Pharmaceutical Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A